 | |
| Clinical data | |
|---|---|
| Other names | Mo 876; DMA |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H24N2OS |
| Molar mass | 340.49 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Botiacrine (INNTooltip International Nonproprietary Name; developmental code nameMo 876) is adrug of thetricyclic family described as anantiparkinsonian agent which was either never marketed or was possibly marketed outside of theUnited States.[1][2][3][4][5] It was first described in the literature by 1965.[1] The drug is anacridinederivative and isstructurally related to thetricyclic antidepressantdimetacrine.[1]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information. |
